Dr. Maurer has over 13 years of experience in the development of delivery technologies for conventional chemotherapeutic agents and biopharmaceuticals such as therapeutic antibodies and nucleic acid-based drugs in various academic and industry settings. Previously, as the Principal Scientist at iCell Therapeutics, a Vancouver-based pharmaceutical company with a delivery platform for lipophilic chemo therapeutic agents, he set up the R&D infrastructure, successfully raised NRC-IRAP funding for the early stage development of the company’s lead product and directed all research activities. As a senior scientist at Inex Pharmaceuticals, he headed the formulation group. He managed the discovery research programs and was actively involved in early and late stages of clinical product development supporting out-licensing of 3 liposomal anticancer drugs for over US $40M. Dr. Maurer has a PhD in Physical Chemistry and completed his post-doctoral training in the Biochemistry Department (The Liposome Research Unit) of the University of British Columbia. He authored 27 peer-reviewed papers, review articles and book chapters and is an inventor on 6 patents/patent applications that support the product pipeline of 4 biotech companies. He also wrote and contributed to scientific grants, business and strategic plans resulting in $7 M in funding.